Johnson & Johnson said the U.S. Food and Drug Administration approved its once-daily psoriasis pill, the first oral option to ...
AbbVie (ABBV) fell ~4% on Wednesday as BNP Paribas argued that its immunology blockbuster Skyrizi could face competition from Icotyde, a newly approved plaque psoriasis pill developed by Johnson & ...
The clearance is the first for an oral peptide that blocks IL-23, the target of popular medicines like Skyrizi and Tremfya. J ...
Johnson & Johnson won U.S. approval for a daily psoriasis pill that rivals the benefits of injectable medicines and could ...
Johnson & Johnson and Protagonist Therapeutics are countering the swarm of injectable biologics that have long dominated the lucrative psoriasis market with a new approval for a much-anticipate | The ...
AbbVie (ABBV) dropped 4.69% after FDA approved J&J's Icotyde psoriasis pill, creating fresh competition for blockbuster drug Skyrizi.
Amgen’s Otezla was the subject of a spoof pharma ad that ran during SNL’s most recent episode. The ad, featuring actor Ryan Gosling, poked fun at the supposed mystery behind the medication and its ...
Skyrizi was the top Rx and over-the-counter (OTC) pharma brand during July, according to data released by iSpot.tv on Monday afternoon. Skyrizi recorded an impressions share of voice (SOV) of 5.18%, ...
In early March 2026, AbbVie reported positive topline Phase 3 AFFIRM data showing risankizumab (SKYRIZI) subcutaneous ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results